The FDA is highly encouraging that all pharmaceutical/biotech sponsors adhere to the CDISC SDTM dataset standards for all new NDA Submissions to the agency. For most firms, this means that sponsors will need to convert all legacy studies to the CDISC SDTM standards for datasets to be submitted as part of their New Drug application to the agency, and to ensure that all future studies address this requirement from a proactive perspective.
- So what does this mean to sponsors?
- What aspects of these requirements should sponsors consider performing in-house (internally)?
- What aspects of these requirements should sponsors consider outsourcing?
- Are there specific components that lend themselves more readily to performing these conversions internally and/or externally?
- What is the amount of effort and time required for each strategy?
- What about ADaM?
TAKE Solutions invites you to attend a seminar on the different aspects of addressing this issue One aspect is from a prospective approach to CDISC SDTM standards (data collection – what to in-source and what to outsource). The other aspect is from a legacy studies perspective for future submissions or data warehousing purposes. TAKE brings to you three experienced speakers for this event who will provide a 360 degree perspective (vendors & sponsors) on these new recommendations from the FDA.
AGENDA
2:00 - 3:00pm Seminar on prospective approach to CDISC standards from data collection. What to in-source and what to outsource?
3:00 - 3:30pm Q & A – Discussion Panel
3:30 - 4:30pm Seminar on legacy studies and data warehousing purposes. What to in-source and what to outsource?
4:30 - 5:00pm Q & A – Discussion Panel
5:00 – 6:00pm Networking/Cocktail Hour
Register now to know more about the efforts required to perform the conversion activities and e-submission activities including Define.xml.